Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) PT at $129.56

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given an average recommendation of “Moderate Buy” by the nineteen brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $129.5625.

A number of research analysts have recently issued reports on the stock. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Citigroup cut their target price on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $130.00 price target on shares of BioNTech in a report on Monday, April 27th. Finally, Berenberg Bank lowered their price target on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, May 12th.

Insider Buying and Selling at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC grew its holdings in BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. EFG International AG acquired a new stake in BioNTech during the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd grew its holdings in BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after acquiring an additional 260 shares during the period. Huntington National Bank grew its holdings in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after acquiring an additional 380 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

NASDAQ:BNTX opened at $91.22 on Thursday. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The firm has a 50 day moving average of $93.96 and a 200-day moving average of $97.92. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $23.07 billion, a P/E ratio of -15.51 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The firm had revenue of $1.06 billion during the quarter. As a group, sell-side analysts anticipate that BioNTech will post -5.67 EPS for the current fiscal year.

BioNTech announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.